ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
ResMed Dividend Announcement
• ResMed announced a quarterly dividend of $0.53 per ordinary share which will be made payable on 2024-12-12. Ex dividend date: 2024-11-07
• ResMed annual dividend for 2024 was $2.02
• ResMed annual dividend for 2023 was $1.84
• ResMed's trailing twelve-month (TTM) dividend yield is 1.09%
• ResMed's payout ratio for the trailing twelve months (TTM) is 26.02%
• ResMed's dividend growth over the last five years (2018-2023) was 5.02% year
• ResMed's dividend growth over the last ten years (2013-2023) was 8.16% year
ResMed Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-07 | $0.53 | quarterly | 2024-12-12 |
2024-08-15 | $0.53 | quarterly | 2024-09-19 |
2024-05-08 | $0.48 | quarterly | 2024-06-13 |
2024-02-07 | $0.48 | quarterly | 2024-03-14 |
2023-11-08 | $0.48 | quarterly | 2023-12-14 |
2023-08-16 | $0.48 | quarterly | 2023-09-21 |
2023-05-10 | $0.44 | quarterly | 2023-06-15 |
2023-02-08 | $0.44 | quarterly | 2023-03-16 |
2022-11-09 | $0.44 | quarterly | 2022-12-15 |
2022-08-17 | $0.44 | quarterly | 2022-09-22 |
2022-05-11 | $0.42 | quarterly | 2022-06-16 |
2022-02-09 | $0.42 | quarterly | 2022-03-17 |
2021-11-09 | $0.42 | quarterly | 2021-12-16 |
2021-08-18 | $0.42 | quarterly | 2021-09-23 |
2021-05-12 | $0.39 | quarterly | 2021-06-17 |
2021-02-10 | $0.39 | quarterly | 2021-03-18 |
2020-11-10 | $0.39 | quarterly | 2020-12-17 |
2020-08-19 | $0.39 | quarterly | 2020-09-24 |
2020-05-13 | $0.39 | quarterly | 2020-06-18 |
2020-02-12 | $0.39 | quarterly | 2020-03-19 |
2019-11-06 | $0.39 | quarterly | 2019-12-12 |
2019-08-14 | $0.39 | quarterly | 2019-09-19 |
2019-05-08 | $0.37 | quarterly | 2019-06-13 |
2019-02-06 | $0.37 | quarterly | 2019-03-14 |
2018-11-07 | $0.37 | quarterly | 2018-12-13 |
2018-08-15 | $0.37 | quarterly | 2018-09-20 |
2018-05-09 | $0.35 | quarterly | 2018-06-14 |
2018-02-07 | $0.35 | quarterly | 2018-03-15 |
2017-11-08 | $0.35 | quarterly | 2017-12-14 |
2017-08-15 | $0.35 | quarterly | 2017-09-21 |
2017-05-09 | $0.33 | quarterly | 2017-06-15 |
2017-02-07 | $0.33 | quarterly | 2017-03-16 |
2016-11-08 | $0.33 | quarterly | 2016-12-15 |
2016-08-16 | $0.33 | quarterly | 2016-09-22 |
2016-05-17 | $0.30 | quarterly | 2016-06-16 |
2016-02-09 | $0.30 | quarterly | 2016-03-17 |
2015-11-17 | $0.30 | quarterly | 2015-12-17 |
2015-08-18 | $0.30 | quarterly | 2015-09-17 |
2015-05-19 | $0.28 | quarterly | 2015-06-18 |
2015-02-10 | $0.28 | quarterly | 2015-03-19 |
2014-11-18 | $0.28 | quarterly | 2014-12-18 |
2014-08-19 | $0.28 | quarterly | 2014-09-18 |
2014-05-16 | $0.25 | quarterly | 2014-06-17 |
2014-02-14 | $0.25 | quarterly | 2014-03-19 |
2013-11-15 | $0.25 | quarterly | 2013-12-18 |
2013-08-16 | $0.25 | quarterly | 2013-09-17 |
2013-05-17 | $0.17 | quarterly | 2013-06-18 |
2013-02-14 | $0.17 | quarterly | 2013-03-19 |
ResMed Dividend per year
ResMed Dividend growth
ResMed Dividend Yield
ResMed current trailing twelve-month (TTM) dividend yield is 1.09%. Interested in purchasing ResMed stock? Use our calculator to estimate your expected dividend yield:
ResMed Financial Ratios
ResMed Dividend FAQ
Other factors to consider when evaluating ResMed as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy ResMed stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: ResMed's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, ResMed publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, ResMed distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from ResMed are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: ResMed sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, ResMed distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: ResMed declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of ResMed's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review ResMed's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.